Trials / Sponsors / Revolution Medicines, Inc.
Revolution Medicines, Inc.
Industry · 16 registered clinical trials — 10 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Ad Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC | Phase 3 | 2026-03-09 |
| Recruiting | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | 2026-01-30 |
| Recruiting | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma | Phase 1 | 2026-01-08 |
| Recruiting | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 3 | 2025-12-15 |
| Recruiting | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC | Phase 3 | 2025-05-06 |
| Active Not Recruiting | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Aden Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 3 | 2024-10-16 |
| Recruiting | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | 2024-05-24 |
| Recruiting | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer | Phase 1 / Phase 2 | 2024-01-18 |
| Recruiting | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced K Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | 2023-11-14 |
| Recruiting | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | 2023-09-07 |
| Active Not Recruiting | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Sol Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma | Phase 1 | 2022-09-19 |
| Recruiting | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 / Phase 2 | 2022-05-31 |
| Completed | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior S Non-Small Cell Lung Cancer | Phase 2 | 2021-12-30 |
| Completed | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors Solid Tumors | Phase 1 | 2021-04-07 |
| Completed | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC Solid Tumor | Phase 1 / Phase 2 | 2019-07-02 |
| Unknown | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors Solid Tumors | Phase 1 | 2018-09-28 |